HomeUSASpringTide Ventures Closes $65M Fund II

SpringTide Ventures Closes $65M Fund II

SpringTide Ventures, a Boston, Salt Lake City, and San Francisco-based early-stage HealthTech venture capital firm, closed its Fund II, at $65m.

The new fund will continue the firm’s commitment to driving innovation and elevating health globally through investments in digital health, medical devices, life sciences, and tech-enabled care delivery.

Led by Austin Walters, Managing Partner, SpringTide Ventures strategically aligns its investments by engaging with industry experts and insiders to identify key trends and opportunities. The firm then proactively seeks out founders and entrepreneurs at the forefront of healthcare innovation, particularly those harnessing advanced technologies to address pressing challenges. Technologies such as artificial intelligence, next-generation sequencing, and flexible electronics are leveraged to create solutions that enhance patient care, improve health outcomes, and broaden access to quality healthcare services.

SpringTide Ventures currently has $100m in total assets under management. Achievements from the portfolio include:

  • GreatExpectations.io: a data quality tooling company, which recently surpassed a rate of over 15 million downloads per month.
  • Pathology Watch, an end-to-end dermatopathology software platform, including AI interpretation, which was acquired by Sonic Healthcare in January 2024, for $150 million.
  • Debut Biotech, a cell-free biomanufacturing company that launched its own skin care product line in 2023, raised a $20m Series B led by L’Oreal.
  • OpenLoop, an end-to-end telemedicine enablement company surpassed $100 million in annualized revenues in early 2024.